Checkpoint Capital L.P. Cytokinetics Inc Transaction History
Checkpoint Capital L.P.
- $202 Billion
- Q3 2024
A detailed history of Checkpoint Capital L.P. transactions in Cytokinetics Inc stock. As of the latest transaction made, Checkpoint Capital L.P. holds 466,813 shares of CYTK stock, worth $22.3 Million. This represents 12.23% of its overall portfolio holdings.
Number of Shares
466,813
Previous 190,000
145.69%
Holding current value
$22.3 Million
Previous $10.3 Billion
139.43%
% of portfolio
12.23%
Previous 6.21%
Shares
3 transactions
Others Institutions Holding CYTK
# of Institutions
410Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$701 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$562 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$463 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$371 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$309 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.5B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...